2.80
-0.085(-2.95%)
Currency In CHF
Address
Wagistrasse 14
Schlieren, 8952
Switzerland
Phone
41 44 755 77 00
Sector
Healthcare
Industry
Biotechnology
Employees
158
First IPO Date
March 03, 2015
| Name | Title | Pay | Year Born |
| Dr. Patrick Amstutz Ph.D. | Co-Founder, Chief Executive Officer, Member of Management Board & Director | 652,000 | 1975 |
| Mr. Michael Pitzner | General Counsel, Compliance Officer, Senior Vice President Legal & Business Development | 0 | N/A |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant | 0 | 1956 |
| Mr. Daniel Steiner Ph.D. | Senior Vice President of Research & Technology | 0 | N/A |
| Mr. Seth D. Lewis | Senior Vice President of Investor Relations, Communications & Strategy | 0 | N/A |
| Mr. Robert Hendriks | Senior Vice President of Finance | 0 | N/A |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive Vice President of Projects & Member of Management Board | 0 | 1972 |
| Ms. Renate Gloggner | Executive Vice President of People & Community and Member of Management Board | 0 | 1970 |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer & Member of the Management Board | 0 | 1966 |
| Mr. Alexander Zurcher | Chief Operating Officer & Member of Management Board | 0 | 1975 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.